Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Drug treatment options for irritable bowel syndrome - Managing for success
Autore:
Dunphy, RC; Verne, GN;
Indirizzi:
Univ Florida, Dept Med, Div Gastroenterol Hepatol & Nutr, Gainesville, FL USA Univ Florida Gainesville FL USA erol Hepatol & Nutr, Gainesville, FL USA
Titolo Testata:
DRUGS & AGING
fascicolo: 3, volume: 18, anno: 2001,
pagine: 201 - 211
SICI:
1170-229X(2001)18:3<201:DTOFIB>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
FUNCTIONAL GASTROINTESTINAL DISORDERS; KAPPA-AGONIST FEDOTOZINE; CHINESE HERBAL MEDICINE; CLINICAL-PHARMACOLOGY; RECEPTOR ANTAGONISTS; CONTROLLED TRIAL; DIETARY FIBER; SMOOTH-MUSCLE; ARTICLE; CONSTIPATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
61
Recensione:
Indirizzi per estratti:
Indirizzo: Verne, GN Malcolm Randall VAMC, 111C,1601 SW Archer Rd, Gainesville, FL 32608 USA Malcolm Randall VAMC 111C,1601 SW Archer Rd Gainesville FL USA 32608
Citazione:
R.C. Dunphy e G.N. Verne, "Drug treatment options for irritable bowel syndrome - Managing for success", DRUG AGING, 18(3), 2001, pp. 201-211

Abstract

Irritable bowel syndrome (IBS) is a functional gut disorder the diagnosis of which is based on clinical symptoms as set forth by the Rome criteria. As the population ages, especially with the population of patients >75 yearsof age expanding greatly over the next 10 years, IBS is becoming one of the most common diseases of the elderly. Thus far, developing treatment strategies for patients with IBS has been difficult because of the lack of pharmacological targets and the wide range of symptomatology. Additionally, demonstration of a therapeutic benefit is difficult in the presence of a high placebo response observed regardless of the therapy employed. Fibre, antidiarrhoeals and antispasmodics all play some role in the symptomatic treatmentof IBS. With the evolution of IBS as a disorder of visceral hypersensitivity, new drugs have been developed that target the enteric nervous system. Tricyclic antidepressants (TCAs) have been found to target the enteric neurons and play a role in pain modulation. Currently, the TCAs are recommended only for severe cases of IBS pain. The newest class of drugs to be approvedfor use in IBS are the serotonin (5-hydroxytryptamine; 5-HT) antagonists. Specifically, the 5-HT3 receptor antagonists have been shown to decrease symptoms in female patients with IBS. A related class of drugs, the 5-HT4 receptor agonists, is being developed for the treatment of constipation-predominant IBS. Further investigation into the role of spinal afferent neurons in visceral hypersensitivity is at the forefront of IBS research. Several experimental drug therapies for IBS are also discussed in this review including N-methyl-D-aspartate receptor antagonists, neurokinin-1 receptor antagonists, octreotide, clonidine and the selective M3 receptor antagonist, zamifenacin.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 00:13:17